Sunitinib-induced pseudoporphyria
2014; Wiley; Volume: 29; Issue: 9 Linguagem: Inglês
10.1111/jdv.12539
ISSN1468-3083
AutoresV. Sanz‐Motilva, A. Martorell, B. Llombart, Celia Requena, C. Serra‐Guillén, Eduardo Nagore, C. Guillén, V. Través, O. Sanmartín,
Tópico(s)Lymphoma Diagnosis and Treatment
ResumoJournal of the European Academy of Dermatology and VenereologyVolume 29, Issue 9 p. 1848-1850 Letter to the Editor Sunitinib-induced pseudoporphyria V. Sanz-Motilva, Corresponding Author V. Sanz-Motilva Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainCorrespondence: V. Sanz-Motilva. E-mail: [email protected]Search for more papers by this authorA. Martorell-Calatayud, A. Martorell-Calatayud Department of Dermatology, Hospital de Manises, Valencia, SpainSearch for more papers by this authorB. Llombart, B. Llombart Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Requena, C. Requena Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Serra-Guillén, C. Serra-Guillén Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorE. Nagore, E. Nagore Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Guillén, C. Guillén Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorV. Traves, V. Traves Department of Pathology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorO. Sanmartín, O. Sanmartín Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this author V. Sanz-Motilva, Corresponding Author V. Sanz-Motilva Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainCorrespondence: V. Sanz-Motilva. E-mail: [email protected]Search for more papers by this authorA. Martorell-Calatayud, A. Martorell-Calatayud Department of Dermatology, Hospital de Manises, Valencia, SpainSearch for more papers by this authorB. Llombart, B. Llombart Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Requena, C. Requena Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Serra-Guillén, C. Serra-Guillén Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorE. Nagore, E. Nagore Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorC. Guillén, C. Guillén Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorV. Traves, V. Traves Department of Pathology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this authorO. Sanmartín, O. Sanmartín Department of Dermatology, Instituto Valenciano de Oncología, Valencia, SpainSearch for more papers by this author First published: 12 May 2014 https://doi.org/10.1111/jdv.12539Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Korting GW. Porphyria cutanea tarda-like aspects in two prolonged hemodialysis patients. Dermatologica 1975; 150: 58–61. 2Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44: 100–108. 3Reddy H, Horne HL, Maung Z. Skin fragility and blistering secondary to imatinib. Clin Exp Dermatol 2012; 37: 562–573. 4Pérez NO, Esturo SV, Viladomiu Edel A, Moreno AJ, Valls AT. Pseudoporphyria induced by imatinib mesilate. Int J Dermatol 2014; 53: 143–144. 5Berghoff AT, English JC III. Imatinib mesylate-induced pseudoporphyria. J Am Acad Dermatol 2010; 63: e14–e16. 6Timmer-de Mik L, Kardaun SH, Kramer MHH, Hayes DP, Bousema MT. Imatinib-inducedpseudoporphyria. Clin Exp Dermatol 2009; 34: 705–707. 7Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107–113. 8Blumenthal GM, Cortazar P, Zhang JJ et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 2012; 17: 1108–1113. 9Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. British J Dermatol 2009; 161: 1045–1051. 10Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19: 40–47. 11Verma SM, Murphy G. Skin fragility and blistering with imatinib mesylate. J Eur Acad Dermatol Venereol 2010; 24: 496–498. Citing Literature Volume29, Issue9September 2015Pages 1848-1850 ReferencesRelatedInformation
Referência(s)